Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are indicated for type 2 diabetes mellitus (T2DM) and obesity and show preliminary evidence of efficacy in addiction-related behaviours. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.